1 Comment
Jul 10, 2022Liked by Paulius Mui, MD

For what it's worth, I think that starting with a use case is far better than a definition (ive been a member of DTA, participated in AMCPs forums, etc etc) and I am convinced that what we have here is a positioning issue not a definitional one. If we have clarity around setting / site of care, stage of disease (1st line, second line intervention etc) it will help resolve a lot of the confusion. As part of this, saying something like "you can try X instead of Y" makes a clear case for subsitition. Many DTx products can be tried prior to starting a pharmacological approach for example.

Expand full comment